MDR-Compliant Biocompatibility Testing Strategies

Medical equipment requires proven biological safety throughout its lifecycle. This study combines an effective, MDR-appropriate biocompatibility investigation plan in accordance with the EU 2017/745 and ISO 10993 families. It describes biocompatibility as a risk-managed program that begins with a Biological Evaluation Plan (BEP), which includes the incorporation of device/material characterization and focuses on chemical characterization (ISO 10993-18) and toxicological risk assessment (ISO 10993-17) to reduce the use of animals. Some of the quantitative data mentioned feature reported recalls due to biocompatibility (∼ 5%–10%), elevated initial MDR non-conformance due to incomplete biological assurance (≈80%), and higher final success rate upon protocol reinforcement and reporting (e.g., second-round approvals after initial failures). These approaches focus on extractables/leachables investigations at polar/non-polar, time, and temperature stressing, with LC-/GCMS analytics support, paired with in vitro cytotoxicity, irritation, and sensitization as initial tests, and in vivo studies, as appropriate, sporadically. Special consideration is paid to CMR and endocrine-disrupting substances according to Annex I 10.4 (threshold ≥ 0.1% w/w), the replacement/labeling determinations, and closing of the gap of the old devices. The Biological Evaluation Report (BER) consolidates the outcomes, deviations, and justification residuals, unlike PMS/PMCF trend data, which maintains perpetual re-evaluation. The result is an actionable blueprint that is statistically based, documentation-ready, and can be adopted by manufacturers who wish to have a comprehensive blueprint that is robust and audit-defended when it comes to compliance and patient safety of the MDR. KPIs track first-pass rates, time of nonconformity closing, and E&L coverage of necessary submissions, which is now approximately 85% of the objective targets of CAPA triggers.